[HTML][HTML] Clinical trials and their impact on policy during COVID-19: a review
Background Of over 8,000 recorded randomised trials addressing COVID-19, around 80%
were of treatments, and 17% have reported results. Approximately 1% were adaptive or …
were of treatments, and 17% have reported results. Approximately 1% were adaptive or …
[HTML][HTML] The race for clinical trials on Omicron-based COVID-19 vaccine candidates: Updates from global databases
SG Viveiros-Rosa, CDS Mendes, GG Farfán-Cano… - Narra J, 2022 - ncbi.nlm.nih.gov
Abstract The coronavirus disease 2019 (COVID-19) has caused more than 6.5 million
deaths globally as of June 10, 2022. The severe acute respiratory syndrome coronavirus 2 …
deaths globally as of June 10, 2022. The severe acute respiratory syndrome coronavirus 2 …
Open Innovation and Regulatory Challenges in New Modality Development: The Pivotal Role of Contract Development and Manufacturing Organisations in …
H Yoshiura, Y Kawata, S Sengoku - Therapeutic Innovation & Regulatory …, 2024 - Springer
Background Ensuring regulatory-compliant manufacturing capability is an essential
challenge for new treatment modalities, but its internalisation is not easy for pharmaceutical …
challenge for new treatment modalities, but its internalisation is not easy for pharmaceutical …
Patent profile for the approved and in clinical trials Mpox vaccines
I der Weid, CU de Souza Mendes… - Pharmaceutical …, 2023 - Taylor & Francis
Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148
deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment …
deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment …
[PDF][PDF] Innovations for remdesivir to remain in the game against COVID-19
The compound has also been evaluated in preclinical studies for a putative treatment of
infections caused by severe acute respiratory syndrome coronavirus (SARS-CoV) and …
infections caused by severe acute respiratory syndrome coronavirus (SARS-CoV) and …
Open Innovation and Regulatory Challenges in New Modality Development: The Pivotal Role of CDMOs in Advancing Antibody Drugs
H Yoshiura, Y Kawata, S Sengoku - 2024 - researchsquare.com
Background Ensuring regulatory-compliant manufacturing capability is an essential
challenge for new treatment modalities, but its internalisation is not easy for pharmaceutical …
challenge for new treatment modalities, but its internalisation is not easy for pharmaceutical …
[PDF][PDF] Unfavorable outcomes in the search for antiviral drugs for COVID-19 treatment.
WC Santos - researchgate.net
Aside from this inexplicable chaotic therapeutic event, reports on the difficulty of getting
Paxlovid have been raised. The high prices of the medicine, unequal distribution, and even …
Paxlovid have been raised. The high prices of the medicine, unequal distribution, and even …